Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors

With the widespread application of immune checkpoint blocking antibodies (ICBs) for the treatment of advanced cancer, immunotherapy has proven to be capable of yielding unparalleled clinical results. However, despite the initial success of ICB-treatment, still a minority of patients experience durable responses to ICB therapy. A plethora of mechanisms underlie ICB resistance ranging from low immunogenicity, inadequate generation or recruitment of tumor-specific T cells or local suppression by stromal cells to acquired genetic alterations leading to immune escape.

Source: Cytokine and Growth Factor Reviews - June 28, 2017 Category: Molecular Biology Authors: Floris Dammeijer, Sai Ping Lau, Casper H.J. van Eijck, Sjoerd H. van der Burg, Joachim G.J.V. Aerts Tags: Mini review Source Type: research